TEL AVIV, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. The presentation will begin at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time). To access a live webcast of the presentation, visit Teva’s Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations. An archived version o ...

Core Viewpoint - Teva Pharmaceutical Industries Ltd. has received upgrades in its credit ratings from S&P Global Ratings and Moody's, indicating significant progress towards achieving investment-grade status [1][7]. Financial Performance - S&P upgraded Teva's long-term issuer credit rating to 'BB+' from 'BB', with a stable outlook, while Moody's affirmed a B1a rating and revised the outlook to positive from stable [1][7]. - Teva's adjusted leverage declined to 4.4x as of September 30, 2025, with expectations to fall below 4.25x in the coming quarters, meeting the threshold for a higher rating [2]. - Moody's noted expectations for leverage to decline toward 3.5x within 12–18 months, supporting the positive outlook [3]. Business Strategy - Teva's financial discipline and strong business performance have been highlighted, with a return to revenue growth after five years of declines, driven by robust performance in branded medicines and stabilization in generics [2]. - The company is focusing on its "Pivot to Growth" strategy, emphasizing cash flow management and capital allocation to support deleveraging and sustainable growth [4]. Product Development - Moody's cited strong momentum in Teva's branded franchises and upcoming product launches across both branded and biosimilar portfolios, which are expected to offset challenges in the generics segment [3].

Core Viewpoint - Teva Pharmaceutical Industries Ltd. has received upgrades in its credit ratings from S&P Global Ratings and Moody's, indicating significant progress towards achieving investment-grade status [1][7]. Group 1: Credit Rating Upgrades - S&P upgraded Teva's long-term issuer credit rating to 'BB+' from 'BB' with a stable outlook [1]. - Moody's affirmed Teva's B1a rating and revised the outlook to positive from stable [3][7]. Group 2: Financial Performance and Strategy - Teva's adjusted leverage declined to 4.4x as of September 30, 2025, with expectations to fall below 4.25x in the coming quarters, which meets the threshold for a higher rating [2]. - The company has returned to revenue growth after five years of declines, driven by strong performance in branded medicines and stabilization in generics [2]. - Moody's highlighted Teva's strong momentum in branded franchises and upcoming product launches, which are expected to offset challenges in the generics segment [3]. Group 3: Management Commentary - Teva's Chief Financial Officer emphasized that the upgrades reflect the company's strategic vision and disciplined execution, particularly through its Pivot to Growth strategy and robust cash flow management [4].

Teva Pharmaceutical Industries (NYSE:TEVA) FY 2025 Conference December 04, 2025 10:30 AM ET Company ParticipantsTraver Davis - Healthcare Sector SpecialistRichard Francis - President and CEOTraver DavisJust continuing on the third and final day of our Citi Global Healthcare Conference. I'm Traver Davis, Healthcare Sector Specialist at Citi, and we're delighted to have Teva with us. From the company, we have Richard Francis, President and CEO. Thanks for joining us. Maybe to start, just hand the floor to you ...

Core Insights - Teva Pharmaceuticals has received marketing authorizations from the European Commission for two denosumab biosimilar candidates, PONLIMSI and DEGEVMA, following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) earlier this year [1][9]. Group 1: Product Approvals - The approvals of PONLIMSI and DEGEVMA represent a significant milestone in Teva's biosimilars portfolio, enhancing patient access to essential biologic therapies across Europe [2][9]. - Teva plans to launch both products in key European markets in the coming months, aligning with its Pivot to Growth strategy [2][9]. Group 2: Product Details - PONLIMSI is indicated for the treatment of osteoporosis in postmenopausal women and men at increased risk of fractures, as well as for bone loss associated with hormone ablation in men with prostate cancer [4][6]. - DEGEVMA is indicated for the prevention of bone complications in adults with advanced cancer involving bone and for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone [7][10]. Group 3: Mechanism of Action - Both PONLIMSI and DEGEVMA contain denosumab, a human monoclonal IgG2 antibody that targets the protein RANKL, crucial for the formation and survival of osteoclasts, thereby reducing bone resorption [5][8]. - PONLIMSI will be available as a 60mg/1mL solution for injection in a pre-filled syringe, while DEGEVMA will be available as a 120mg/1.7mL solution for injection in a vial [5][8]. Group 4: Company Commitment - Teva's leadership emphasizes the importance of these approvals in increasing patient access to biosimilar therapies for serious bone conditions, reflecting the company's commitment to improving healthcare options in Europe [3][9]. - The company aims to provide additional treatment options for healthcare systems, particularly in regions where access to biosimilars is limited [3].

Core Viewpoint - Teva Pharmaceutical Industries Ltd. is set to present at three investor conferences in December 2025, highlighting its ongoing transformation into a leading innovative biopharmaceutical company supported by a robust generics business [1][3]. Company Overview - Teva has a history of over 120 years in the pharmaceutical industry, focusing on improving health through innovation in neuroscience, immunology, complex generics, biosimilars, and pharmacy brands globally [3]. Upcoming Events - The company will participate in the following conferences: - 8th Annual Evercore Healthcare Conference on December 3, 2025, at 8:20 A.M. ET - Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, at 11:00 A.M. ET - Citi's 2025 Global Healthcare Conference on December 4, 2025, at 10:30 A.M. ET [5].

Core Viewpoint - Curtiss-Wright Corporation reported strong financial results for Q3 2025, leading to an increase in full-year guidance for sales, operating income, and diluted EPS, driven by the successful implementation of its "Pivot to Growth" strategy [1][2]. Financial Performance - Reported sales reached $869 million, a 9% increase from Q3 2024, with operating income of $166 million, reflecting a 15% growth [3][5]. - Adjusted operating income was $170 million, up 14%, with an adjusted operating margin of 19.6%, an increase of 90 basis points [5][6]. - Diluted EPS increased to $3.31, with adjusted diluted EPS at $3.40, both up 14% year-over-year [5][6]. Segment Performance - **Aerospace & Industrial**: Sales of $248 million, up 8%, with operating income of $45 million, a 21% increase [4][11]. - **Defense Electronics**: Sales of $253 million, a 4% increase, with operating income of $74 million, up 16% [7][12]. - **Naval & Power**: Sales of $368 million, a 12% increase, with operating income of $58 million, up 9% [8][13]. Order and Backlog - New orders totaled $927 million, an 8% increase, resulting in a book-to-bill ratio of 1.1x [5][14]. - The backlog increased to $3.9 billion, reflecting a 14% growth year-to-date [5][14]. Cash Flow and Capital Allocation - Free cash flow for Q3 2025 was $176 million, an 8% increase, with a conversion rate of 137% [9][14]. - The company expanded its share repurchase program, targeting over $450 million in annual repurchases, indicating confidence in future performance [2][14]. Updated Guidance - Full-year 2025 sales guidance was raised to a range of $3,420 million to $3,455 million, reflecting a growth of 10% to 11% [15]. - Operating income guidance was increased to $634 million to $647 million, representing a growth of 16% to 19% [15]. - Diluted EPS guidance was updated to a range of $12.95 to $13.20, indicating a growth of 19% to 21% [15].

Q3 2025 Financial Performance - Revenues reached $4480 million, a 3% increase year-over-year[21, 93] - Adjusted EBITDA was $1400 million, up by 6% compared to the previous year[21] - Non-GAAP EPS increased by 14% to $078[21] - Free Cash Flow was $500 million[21] AUSTEDO Performance and Outlook - AUSTEDO U S revenues grew by 38% year-over-year to $601 million in Q3 2025[32] - AUSTEDO global revenues grew by 38% year-over-year to $618 million in Q3 2025[25] - The company reaffirmed its 2027 sales target for AUSTEDO at over $25 billion[29, 58] Pipeline and Strategic Updates - UZEDY revenues in Q3 2025 reached $43 million, a 24% increase year-over-year[25, 36] - The company reaffirmed its 2025 revenue outlook for UZEDY at $190 million - $200 million[35] - Global revenues for AJOVY reached $168 million in Q3 2025, a 19% increase year-over-year[25, 46] - The company is targeting olanzapine LAI FDA submission in Q4 2025[48, 63]

Teva's Pipeline and Capabilities - Teva has in-house R&D experts with a proven track record in developing neuroscience products at all stages of development[15] - Teva has substantial, experienced commercial neuroscience teams[16] Schizophrenia Market and Unmet Needs - There are an estimated ~47 million prevalent schizophrenia patients in the US and Europe[35] - Approximately 23 million patients are diagnosed, and ~21 million are treated[39] - Long untreated psychosis is associated with poor long-term outcomes[21] - Suboptimal medication adherence is a major modifiable risk factor for relapse, highlighting the need for LAIs[22] Teva's Olanzapine LAI (TEV-'749) - Teva's olanzapine LAI met primary and key secondary efficacy endpoints at all 3 doses[30] - The efficacy and systemic safety profile of Teva's olanzapine LAI is comparable to daily oral olanzapine, with no PDSS to date[30] - Approximately 4,000 subcutaneous injections across multiple clinical studies, with no PDSS observed[30] - All TEV-'749 doses exhibited long-term, continuous symptom improvement and maintenance of clinical effectiveness in the SOLARIS study[59] - No suspected or confirmed PDSS events were reported in 3470 injections[59] Commercial Opportunity - Teva aims to be the preferred LAI for patients appropriate for oral risperidone or paliperidone and modestly controlled patients seeking additional convenience[34] - Teva is addressing a broad spectrum of patients with UZEDY and olanzapine LAI, with 65%-80% of patients having the potential to switch as they are currently on a similar molecule[45] - Teva anticipates franchise peak sales expectation of $15 billion-$20 billion for Olanzapine LAI TEV-'749[45]

Company Overview - Teva Pharmaceutical Industries Ltd. is a leading innovative biopharmaceutical company with a strong generics business, committed to addressing patients' needs for over 120 years [2] Upcoming Events - Richard Francis, Teva's President and CEO, will present at two investor conferences in September 2025: Morgan Stanley 23rd Annual Global Healthcare Conference on September 9 at 8:30 A.M. ET and BofA Global Healthcare Conference 2025 in London on September 24 at 9:00 A.M. British Summer Time [1][4] Webcast Information - A live webcast of the presentations will be available on Teva's Investor Relations website, with an archived version accessible within 24 hours after the live discussion [1]